Richard Zare
Direktor/Vorstandsmitglied bei Annual Reviews
Profil
Richard N.
Zare is the founder of Pathwork Diagnostics, Inc. founded in 2003.
He currently holds positions as Co-Chairman & Member at Colby Pharmaceutical Co., Director at The Camille & Henry Dreyfus Foundation, Inc., and Director at Annual Reviews.
His former positions include Chairman at Stanford University, Technical Advisory Board Member at Picarro, Inc. from 2000 to 2012, Assistant Professor at Massachusetts Institute of Technology in 1965, and Professor at the University of Colorado Health Sciences Center from 1966 to 1976.
Dr. Zare received his undergraduate and doctorate degrees from Harvard University in 1961.
Aktive Positionen von Richard Zare
| Unternehmen | Position | Beginn |
|---|---|---|
The Camille & Henry Dreyfus Foundation, Inc.
 The Camille & Henry Dreyfus Foundation, Inc. Financial ConglomeratesFinance Founded in 1946 by Camille Dreyfus, the Camille and Henry Dreyfus Foundation, Inc. is a non-for-profit corporation located in New York City | Corporate Officer/Principal | 19.08.2010 |
Colby Pharmaceutical Co.
 Colby Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Colby is transitioning to a clinical stage drug development company. The company was launched as a Wisconsin Alumni Research Foundation (WARF) spin-out and is strategically aligned with leading clinicians and drug discovery scientists at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center (UWCCC). Colby is accessing data from funded grants and private investment to develop its therapeutic drugs for therapy-resistant and hypoxic conditions. Colby's lead drugs have unique mechanisms of action and target specific pathways. The company is focused on clinical development of its lead drugs, CPC-100 and -200, in patients with recurrent PCa and other solid tumors, respectively. In 2010, Colby plans to launch a Phase I/IIa study of CPC-100 in men with PCa who fail Androgen Depletion Therapy, as evidenced by rising PSA levels. CPC-200 is being scheduled for a Phase I/IIa in men with high-risk tumors. Colby's two pipeline drugs, CPC-300 and CPC-410 for therapy-resistant metastatic and hypoxic tumors are in late pre-clinical development and are funded by federal grants, including an awarded Colby SBIR grant and by private investors. The Company has demonstrated safety of its lead drugs following efficacy studies in rodents and toxicology studies in mice, rats, and dogs. | Corporate Officer/Principal | - |
Annual Reviews
 Annual Reviews Publishing: Books/MagazinesConsumer Services Annual Reviews is an American company that publishes journals. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Richard Zare
| Unternehmen | Position | Ende |
|---|---|---|
Picarro, Inc.
 Picarro, Inc. Packaged SoftwareTechnology Services Picarro, Inc. produces real-time, cloud-based gas measurement solutions for the global energy and scientific markets. The company offers isotope analyzers, trace gas analyzers, peripherals, service packages and parts and supplies. The company was founded by Barbara A. Paldus in January 1998 and is headquartered in Santa Clara, CA. | Corporate Officer/Principal | - |
| University of Colorado Health Sciences Center | Corporate Officer/Principal | 31.12.1976 |
| Massachusetts Institute of Technology | Corporate Officer/Principal | 31.12.1965 |
| Stanford University | Corporate Officer/Principal | - |
Pathwork Diagnostics, Inc.
 Pathwork Diagnostics, Inc. Medical SpecialtiesHealth Technology Pathwork Diagnostics Inc. develops and delivers molecular diagnostics for oncology. The company was founded by Glenda Anderson, Richard Zare, and George M. Whitesides in 2003 and is headquartered in Redwood City, CA. | Gründer | - |
Ausbildung von Richard Zare
| Harvard University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Picarro, Inc.
Picarro, Inc. Packaged SoftwareTechnology Services Picarro, Inc. produces real-time, cloud-based gas measurement solutions for the global energy and scientific markets. The company offers isotope analyzers, trace gas analyzers, peripherals, service packages and parts and supplies. The company was founded by Barbara A. Paldus in January 1998 and is headquartered in Santa Clara, CA. | Technology Services |
Pathwork Diagnostics, Inc.
Pathwork Diagnostics, Inc. Medical SpecialtiesHealth Technology Pathwork Diagnostics Inc. develops and delivers molecular diagnostics for oncology. The company was founded by Glenda Anderson, Richard Zare, and George M. Whitesides in 2003 and is headquartered in Redwood City, CA. | Health Technology |
The Camille & Henry Dreyfus Foundation, Inc.
The Camille & Henry Dreyfus Foundation, Inc. Financial ConglomeratesFinance Founded in 1946 by Camille Dreyfus, the Camille and Henry Dreyfus Foundation, Inc. is a non-for-profit corporation located in New York City | Finance |
Colby Pharmaceutical Co.
Colby Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Colby is transitioning to a clinical stage drug development company. The company was launched as a Wisconsin Alumni Research Foundation (WARF) spin-out and is strategically aligned with leading clinicians and drug discovery scientists at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center (UWCCC). Colby is accessing data from funded grants and private investment to develop its therapeutic drugs for therapy-resistant and hypoxic conditions. Colby's lead drugs have unique mechanisms of action and target specific pathways. The company is focused on clinical development of its lead drugs, CPC-100 and -200, in patients with recurrent PCa and other solid tumors, respectively. In 2010, Colby plans to launch a Phase I/IIa study of CPC-100 in men with PCa who fail Androgen Depletion Therapy, as evidenced by rising PSA levels. CPC-200 is being scheduled for a Phase I/IIa in men with high-risk tumors. Colby's two pipeline drugs, CPC-300 and CPC-410 for therapy-resistant metastatic and hypoxic tumors are in late pre-clinical development and are funded by federal grants, including an awarded Colby SBIR grant and by private investors. The Company has demonstrated safety of its lead drugs following efficacy studies in rodents and toxicology studies in mice, rats, and dogs. | Health Technology |
Annual Reviews
Annual Reviews Publishing: Books/MagazinesConsumer Services Annual Reviews is an American company that publishes journals. | Consumer Services |
